Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Tg Therapeuticscmn (TGTX)

Tg Therapeuticscmn (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Tg Therapeuticscmn 3020 CARRINGTON MILL BLVD SUITE 475 MORRISVILLE NY 27560 USA

www.tgtherapeutics.com P: 212-554-4484

Description:

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.

Key Statistics

Overview:

Market Capitalization, $K 2,502,051
Enterprise Value, $K 2,509,241
Shares Outstanding, K 154,543
Annual Sales, $ 233,660 K
Annual Net Income, $ 12,670 K
Last Quarter Sales, $ 43,970 K
Last Quarter Net Income, $ -14,420 K
EBIT, $ 20,630 K
EBITDA, $ 21,190 K
60-Month Beta 2.33
% of Insider Shareholders 9.20%
% of Institutional Shareholders 58.58%
Float, K 140,325
% Float 90.80%
Short Volume Ratio 0.32

Growth:

1-Year Return -53.57%
3-Year Return -59.73%
5-Year Return 114.15%
5-Year Revenue Growth 155,673.33%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.07 on 05/01/24
Latest Earnings Date 05/06/24 [--]
Earnings Per Share ttm 0.02
EPS Growth vs. Prev Qtr 22.22%
EPS Growth vs. Prev Year 75.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-56 on 04/27/12

TGTX Ratios

Ratio
Price/Earnings ttm 71.39
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 33.79%
Return-on-Assets % 14.02%
Profit Margin % 5.42%
Debt/Equity 0.62
Price/Sales 10.86
Price/Cash Flow 187.82
Price/Book 15.49
Book Value/Share 1.06
Interest Coverage 2.03
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar